CLOVIS ONCOLOGY, INC. AND THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of April 19, 2018 1.25% Convertible Senior Notes due 2025First Supplemental Indenture • April 19th, 2018 • Clovis Oncology, Inc. • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of April 19, 2018 (“Supplemental Indenture”), by and between CLOVIS ONCOLOGY, INC., a Delaware corporation, as issuer (the “Company”, as more fully set forth in Section 1.01), and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., a national banking association, as trustee (the “Trustee”), that supplements the Indenture, dated as of April 19, 2018 (the “Base Indenture”, and as amended, modified and supplemented by this Supplemental Indenture, the “Indenture”), by and between the Company and the Trustee.
CLOVIS ONCOLOGY, INC. and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee INDENTURE Dated as of April 19, 2018Indenture • April 19th, 2018 • Clovis Oncology, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of April 19, 2018 between Clovis Oncology, Inc. (the “Company”), a Delaware corporation having its principal office at 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301, and The Bank of New York Mellon Trust Company, N.A. with its principal office at 400 South Hope Street, Los Angeles, California 90071 (the “Trustee”). Each party agrees as follows for the benefit of each other party and for the equal and ratable benefit of the Holders of the Company’s debentures, notes or other evidences of unsecured indebtedness to be issued in one or more series (“Securities”):
CLOVIS ONCOLOGY, INC. Underwriting AgreementUnderwriting Agreement • April 19th, 2018 • Clovis Oncology, Inc. • Pharmaceutical preparations • New York
CLOVIS ONCOLOGY, INC. 1,837,898 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • April 19th, 2018 • Clovis Oncology, Inc. • Pharmaceutical preparations • New York
